The GSK plc Board has declared a third interim dividend for Q3 2026 of 17p per share (Q3 2025: 16p per share). The ex-dividend date is 12 November 2026 for ordinary shares, record date is 13 November 2026, and payment date of 7 January 2027 for GSK's Q3 2026 dividend.
Other financial highlights include:
- Total Q3 sales £8.9 billion +4% AER; +5% CER
- Specialty Medicines sales £3.9 billion (+15%); HIV sales £2.1 billion (+10%), Respiratory, Immunology & Inflammation £1.1 billion (+21%); Oncology £0.6 billion (+23%)
- Vaccines sales £2.6 billion (-2%); Shingrix £0.8 billion (-5%); Meningitis vaccines £0.6 billion (+12%); and Arexvy £0.2 billion (-24%)
- General Medicines sales £2.4 billion (stable); Trelegy £0.8 billion (+8%)
- Total operating profit -16% and Total EPS -21% driven by Major restructuring charges of £328 million related to the Accelerate Growth programme and lower other net operating income, partly offset by Core operating profit growth
- Core operating profit +5% and Core EPS +1% reflecting higher sales, favourable product and regional mix and higher royalty income, partly offset by increased investment in R&D and new asset launches and higher finance costs
- Cash generated from operations of £3.1 billion with free cash flow of £2.1 billion
